TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and ...

BioAge is developing structurally distinct APJ agonists in its pipeline ... BioAge is developing its novel, proprietary class of NLRP3 inhibitors, which have distinctive structural and biological ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may increase the risk of pulmonary aspiration among patients undergoing surgery ...

BioAge is developing structurally distinct APJ agonists in its pipeline, with the goal of nominating a development candidate by the end of 2025. • Nomination of NLRP3 inhibitor BGE-102 as a ...

BioAge is developing structurally distinct APJ agonists in its pipeline, with the goal of nominating a development candidate by the end of 2025. • Nomination of NLRP3 inhibitor BGE-102 as a ...

BioAge is developing structurally distinct APJ agonists in its pipeline, with the goal of nominating a development candidate by the end of 2025. • Nomination of NLRP3 inhibitor BGE-102 as a ...

Two months after going public, BioAge stopped a phase 2 trial of its oral apelin receptor agonist azelaprag ... BioAge’s NLRP3 inhibitor has become the biotech’s most advanced prospect.